camrelizumab + albumin-bound paclitaxel + platinum

This is a combination regimen consisting of three agents: **Camrelizumab** is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance the anti-tumor immune response. **Albumin-bound paclitaxel** (also known as nab-paclitaxel or Abraxane) is a microtubule inhibitor formulated with albumin to improve solubility and delivery, disrupting mitosis in cancer cells. **Platinum-based chemotherapy** refers to agents such as cisplatin, carboplatin, or oxaliplatin that form DNA crosslinks, inhibiting DNA synthesis and repair, leading to apoptosis in rapidly dividing tumor cells. This combination has been studied primarily for advanced cancers such as non-small cell lung cancer (NSCLC) and gastric cancer, where it aims to leverage synergistic effects between immunotherapy and cytotoxic chemotherapy[3][5][8]. Camrelizumab enhances immune-mediated tumor killing; albumin-bound paclitaxel increases cytotoxicity while potentially modulating the tumor microenvironment; platinum compounds provide additional antineoplastic activity through direct DNA damage.

Other names

camrelizumab plus albumin-bound paclitaxel and platinumcamrelizumab + nab-paclitaxel + platinumSHR-1210 + Abraxane + platinum